<DOC>
	<DOCNO>NCT02744196</DOCNO>
	<brief_summary>The mail goal study establish superiority efficacy Acellbia® apply dose 600 mg ( Day 1 Day 15 ) combination methotrexate patient active RA seropositive previously untreated biological therapy , compare standard therapy methotrexate .</brief_summary>
	<brief_title>Clinical Trial Evaluate Efficacy Safety Acellbia® ( JSC `` BIOCAD '' ) With Methotrexate First Line Biological Therapy Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Written inform consent . Age 18 80 year . Rheumatoid arthritis diagnose least 6 month inform consent sign Presence 8 swell 8 painful joint screen . Creactive protein 7 mg/l AND/OR erythrocyte sedimentation rate 28 mm/hour . Antibodies citrullinated cyclic peptide 20 U/ml AND/OR rheumatoid factorIgM high upper normal limit . Documented regular methotrexate intake 12 week , stable dose 10 25 mg/week last 4 week sign informed consent . Methotrexate intolerance . Felty 's syndrome . Patient functional status IV class accord ACR . Previous use biologic drug treat rheumatoid arthritis , biologic drug deplete CD20lymphocytes , azathioprine use last 28 day prior informed consent signing , leflunomide use last 8 week prior inform consent signing , sulphasalazine/hydroxyquinoline use last 28 day prior informed consent signing , intraarticular use corticosteroid last 4 week prior inform consent signing , patient require prednisolone ( analogue ) dose 10 mg/day dose unstable 4 week prior inform consent signing , requirement nonsteroid antiinflammatory drug dose stable last 8 week prior inform consent signing . Patient inflammatory joint disease otherwise rheumatoid arthritis systemic autoimmune disease . Full list inclusion exclusion criterion find Study Protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>rheumatism</keyword>
	<keyword>Acellbia</keyword>
	<keyword>methotrexate</keyword>
	<keyword>biologic therapy</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>rituximab</keyword>
</DOC>